You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Marketing Resources for Rural Enterprise Development

    SBC: CEO Praxis Inc            Topic: N/A

    CEO Praxis, Inc. is proposing to research the feasibility of developing an approach for small and medium sized manufacturing enterprises to implement the key steps needed to 1) evaluate market opportunities and trends, 2) build interfirm relationships with customers and/or collaborators, 3) develop marketing strategies, and 4) execute effective marketing tactics. The research will be completed by ...

    SBIR Phase II 1997 Department of Agriculture
  3. A Rapid Collection And Detection Method For

    SBC: Immunological Associates Of Denver            Topic: N/A

    Studies have found Cryptosporidium parvum (C. parvum) oocysts in 65-97% of surface water tested inthe United States. The current Surface Water Treatment Rule does not include analysis for C. parvum.However, the increased incidence of outbreaks involving Cryptosporidiosis have instigated aninvestigation into whether or not testing should be included in the Enhanced Surface Water TreatmentRule. Th ...

    SBIR Phase I 1997 Department of Agriculture
  4. Rural Distributed Manufacturing Systems

    SBC: KILLDEER MOUNTAIN MANUFACTURING            Topic: N/A

    Phase I research will demonstrate the feasibility of the proposed Rural Distributed ManufacturingSystem (RDMS). The RDMS concept has the potential to bring new jobs to rural states.The RDMS is a disciplined framework that ties together technologies and operating techniques todistribute manufacturing work over a region. The RDMS will integrate dispersed laborresources, enabling the manufacture of ...

    SBIR Phase I 1997 Department of Agriculture
  5. A Real-time Cracked Grain Monitor For

    SBC: PHOTON-X, LLC            Topic: N/A

    Phase I research will demonstrate the feasibility of a new cracked grain monitor that can mount directlyonto a combine to detect breakage in a variety of clean grains while they are being harvested. Whenintegrated into a closed-loop threshing control system, this sensor will greatly improve the quality ofgrain by providing real-time monitoring and control of cracked grain percentages, will reduce ...

    SBIR Phase I 1997 Department of Agriculture
  6. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government